Syntara (SNT) Q3 2026 earnings summary

Executive summary

• Positive FDA feedback supports advancement of amsulostat into a Phase 2b trial for myelofibrosis, with study design endorsed and late-stage development enabled.

• Recruitment completed for Phase 2 trial of SNT-4728 in REM Sleep Behaviour Disorder; top-line results expected Q2 CY26.

• Garvan Institute secured A$3 million MRFF grant for pancreatic cancer studies, including amsulostat, with no cash contribution required from Syntara.

• Five clinical data readouts anticipated in 2026, positioning the company for a transformative year.

Financial highlights

• Closing cash balance at 31 March 2026 was $8.9 million, down from $10.5 million at 31 December 2025.

• Net cash outflow from operating activities was $1.6 million for the quarter, improved from $3.8 million in the previous quarter.

• Received A$1.7 million milestone payment from Parkinson's UK for SNT-4728 trial.

• Proforma cash balance post capital raise is $16.9 million, assuming full placement proceeds.

Outlook and guidance

• Cash runway extended to Q3 2027 following successful A$8 million placement and planned A$2 million share purchase plan.

• Focus on delivering five key clinical trial readouts and progressing licensing discussions in 2026.